Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | VITAL results for birtamimab in AL amyloidosis

Morie Gertz • 7 Dec 2019
ASH 2019
Amyloidosis Rare Diseases Antibodies Birtamimab
VITAL

Morie Gertz, MD, MACP, Mayo Clinic College of Medicine, Rochester, MN, discusses the results of the phase III VITAL study of birtamimab (NEOD001), a monoclonal IgG1 antibody, plus standard of care in patients with light chain (AL) amyloidosis. Post hoc analyses suggest a potential survival benefit with NEOD001 for AL amyloidosis patients with the highest risk of early mortality (Mayo stage IV). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Morie Gertz

1:36
Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosis
Morie Gertz • 21 Nov 2022
1:33
The role of allogeneic transplantation in patients with multiple myeloma
Morie Gertz • 21 Nov 2022
1:34
The importance of identifying AH amyloidosis in patients with normal free light chain levels
Morie Gertz • 21 Nov 2022
1:37
MRD as a prognostic tool but not for clinical decision-making in multiple myeloma
Morie Gertz • 21 Nov 2022

Related Videos

1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:59
The common clinical manifestations of BPDCN
Anthony Stein • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals